Peer-reviewed publication highlighting promising safety data and high patient compliance in a clinical trial of AD 04 as a potential treatment for alcohol use disorder
Adial Pharmaceuticals, Inc., announced the publication of a peer-reviewed article highlighting the promising clinical results, strong safety profile and high compliance among patients administered AD 04 (low-dose ondansetron), the Company’s lead investigational new drug product being developed for the treatment of Alcohol Use Disorder (AUD)